Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Kyung-Ah HanSuk ChonChoon Hee ChungSoo LimKwan-Woo LeeSeiHyun BaikChang Hee JungDong-Sun KimKyong Soo ParkKun-Ho YoonIn-Kyu LeeBong Soo ChaTaishi SakataniSumi ParkMoon Kyu LeePublished in: Diabetes, obesity & metabolism (2018)
Ipragliflozin as add-on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM.